Palvella Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations
16 nov. 2023 07h45 HE
|
Palvella Therapeutics
QTORIN™ rapamycin has potential to be first approved therapy and standard of care in the U.S. for Microcystic Lymphatic Malformations Microcystic Lymphatic Malformations is a chronically...
Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434
16 nov. 2023 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update
13 nov. 2023 08h00 HE
|
Benitec Biopharma Inc.
Benitec Biopharma, a genetic medicines company, releases updates on OPMD program and other corporate and financial updates.
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
08 nov. 2023 16h11 HE
|
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results
Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy
08 nov. 2023 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
– ATH434-201 is a randomized, double-blind, placebo-controlled study in early-stage MSA – – Lead clinical development program enrolled 77 participants globally – MELBOURNE, Australia and SAN...
The North America Rare Disease Summit focused on the need for centralized data to improve the lives of 30 million people living with rare conditions
02 nov. 2023 15h51 HE
|
Bamberg Health
Stakeholders debate at the North America Rare Disease Summit on the challenges regarding treatment approvals and the importance of a proactive registry
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®
02 nov. 2023 10h37 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Foundation for Sarcoidosis Research Announces 3 New Members to the 40 Member FSR Global Sarcoidosis Clinic Alliance through its FSR-GSCA Capacity Building Grants
01 nov. 2023 11h26 HE
|
Foundation for Sarcoidosis Research
Foundation for Sarcoidosis Research announces three clinics that have been selected as members of FSR Global Sarcoidosis Clinic Alliance
Spexis Announces Changes to the Executive Committee
01 nov. 2023 02h20 HE
|
Spexis AG
Spexis Announces Changes to the Executive Committee
NovelMed Commences Phase II Trial for Anti-Bb Antibody (NM8074) in Treatment-Naïve PNH Patients: A Glimpse into the PNH Study Progress
30 oct. 2023 08h00 HE
|
NovelMed Therapeutics Inc
The Phase I healthy trial revealed that NM8074 effectively blocked the alternative pathway (AP) and AP-mediated C3b deposition without affecting the classical pathway (CP). Importantly, NM8074 did not...